Neo Ivy Capital Management Incyte Corp Transaction History

Neo Ivy Capital Management

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 29, 2023	BUY	$57.77 - $65.93 $1.03 Million - $1.18 Million	17,908 New	17,908 $1.04 Million
Q4 2022 Mar 24, 2023	BUY	$67.18 - $84.11 $108,159 - $135,417	1,610 Added 121.05%	2,940 $236,000
Q3 2022 Nov 15, 2022	BUY	$66.18 - $82.86 $2,911 - $3,645	44 Added 3.42%	1,330 $89,000
Q2 2022 Aug 16, 2022	SELL	$66.18 - $83.18 $125,874 - $158,208	-1,902 Reduced 59.66%	1,286 $97,000
Q1 2022 May 16, 2022	BUY	$66.02 - $79.71 $65,029 - $78,514	985 Added 44.71%	3,188 $254,000
Q4 2021 Feb 15, 2022	BUY	$63.34 - $74.11 $139,538 - $163,264	2,203 New	2,203 $0
Q3 2021 Nov 16, 2021	SELL	$68.67 - $84.02 $10,506 - $12,855	-153 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$79.87 - $87.53 $12,220 - $13,392	153 New	153 $13,000
Q1 2021 Oct 07, 2021	SELL	$76.02 - $100.5 $143,069 - $189,141	-1,882 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$80.74 - $97.7 $119,333 - $144,400	1,478 Added 365.84%	1,882 $164,000
Q1 2020 May 15, 2020	SELL	$63.18 - $85.97 $482,252 - $656,209	-7,633 Reduced 94.97%	404 $30,000
Q4 2019 Feb 13, 2020	SELL	$73.04 - $95.72 $48,717 - $63,845	-667 Reduced 7.66%	8,037 $702,000
Q3 2019 Nov 21, 2019	BUY	$72.82 - $86.52 $633,825 - $753,070	8,704 New	8,704 $712,000
Q2 2019 Aug 15, 2019	SELL	$73.52 - $88.7 $12,571 - $15,167	-171 Closed	0 $0
Q1 2019 May 15, 2019	SELL	$63.56 - $88.17 $213,307 - $295,898	-3,356 Reduced 95.15%	171 $14,000
Q4 2018 Feb 14, 2019	BUY	$58.5 - $69.94 $206,329 - $246,678	3,527 New	3,527 $224,000

645

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.3B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Neo Ivy Capital Management, based on Form 13F filings with the SEC.

Stay updated on Neo Ivy Capital Management with notifications on news.